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AIMS
Paracetamol is the analgesic most used by older people. The physiological changes occurring with ageing inﬂuence the
pharmacokinetics (PK) of paracetamol and its variability. We performed a population PK-analysis to describe the PK of intravenous
(IV) paracetamol in ﬁt older people. Simulations were performed to illustrate target attainment and variability of paracetamol
exposure following current dosing regimens (1000mg every 6 h, every 8 h) using steady-state concentration (Css-mean) of 10mg l
–1
as target for effective analgesia.
METHODS
A population PK-analysis, using NONMEM 7.2, was performed based on 601 concentrations of paracetamol from 30 ﬁt older
people (median age 77.3 years, range [61.8–88.5], body weight 79 kg [60–107]). All had received an IV paracetamol dose of
1000 mg (over 15 min) after elective knee surgery.
RESULTS
A two-compartment PK-model best described the data. Volume of distribution of paracetamol increased exponentially with body
weight. Clearance was not inﬂuenced by any covariate. Simulations of the standardized dosing regimens resulted in a Css of
9.2 mg l–1 and 7.2 mg l–1, for every 6 h and every 8 h respectively. Variability in paracetamol PK resulted in Css above 5.4 and
4.1 mg l–1, respectively, in 90% of the population and above 15.5 and 11.7, respectively, in 10% at these dosing regimens.
CONCLUSIONS
The target concentration was achieved in the average patient with 1000 mg every 6 h, while every 8 h resulted in underdosing for
the majority of the population. Furthermore, due to a large (unexplained) interindividual variability in paracetamol PK a relevant
proportion of the ﬁt older people remained either under- or over exposed.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Physiological changes occurring with ageing inﬂuence the pharmacokinetics (PK) of intravenous paracetamol and its
variability.
• Although PK of paracetamol have been described, no analysis in older people has been conducted trying to both explain
variability in paracetamol PK as well as to illustrate target attainment (10 mg l–1) following currently dosing regimens.
WHAT THIS STUDY ADDS
• The steady-state target concentration of 10 mg l–1 was achieved with 1000 mg every 6 h and every 8 h (9.2 and 7.2 mg l–1
respectively), resulting in underdosing for the average patient.
• Due to large (unexplained) interindividual variability in paracetamol PK, a relevant proportion of ﬁt older people
remained under- (every 8 h) or over-exposed (every 6 h).
Introduction
The proportion of older people (age > 65 years) in the world
population has increased by 48% from 2000 to 2015 [1].
The number of older people is estimated to increase from
962 million in 2017 to 2.1 and 3.1 billion between 2050
and 2100, respectively [1]. It is expected, therefore, that the
prevalence of diseases associated with advancing age, includ-
ing pain syndromes, will rise.
Older people’s pain management is still often suboptimal
[2]. The most used analgesic in older people is paracetamol
(acetaminophen, APAP) [3], prescribed not only for the man-
agement of chronic pain, but also for acute pain (e.g. postop-
erative pain) [4]. The paracetamol disposition can be affected,
however, by speciﬁc physiological factors such as increased
body fat and decreased renal function, which may explain
suboptimal effect. In addition, great individual variability in
drug disposition may be expected in this very heterogeneous
population.
Drug trials usually exclude older subjects. Therefore, drug
dosages for older people are mostly based on clinical experi-
ence, expert opinion or extrapolations from studies in youn-
ger adults. Intravenous (IV) paracetamol is currently
registered for the short-term treatment of pain at a dose of
1000 mg every 6 h (maximum daily dose 4000 mg) in adults
with a body weight of >50 kg and at a dose of 15 mg kg–1
(maximum daily dose 60 mg kg–1 or 3000 mg) in adults with
a bodyweight of ≤50 kg [5, 6]. As old age in itself is a potential
risk factor for paracetamol toxicity, it has been proposed to
limit dosing to 3000 mg daily, even for adults weighing
>50 kg [7] and to monitor safety parameters (e.g. liver func-
tion test) when IV paracetamol is used for longer than 48 h
[7]. Although there is a lack of evidence supporting dose re-
duction in patients with risk factors [7], IV paracetamol (espe-
cially 1000 mg every 8 h) [8] is widely used in older people.
Several noncompartmental pharmacokinetic (PK)-studies
comparing cohorts of ﬁt older people with cohorts of young
adults found a lower volume of distribution (Vd) of 22.9%
and paracetamol clearance (CL) of 45.7% in the older people
[9, 10]. As the PK analyses showed high variability in PK in
the ﬁt older people, the question is in what way this inﬂu-
ences the exposure to (and thereby the efﬁcacy of) the drug
and if there is a reason to adjust paracetamol dosages.
Adequate analgesia in the paediatric population was
achieved at steady-state concentration (Css-mean) of 10 mg l
–1
[11]. Since this target concentration assumedly holds for
older people as well, although with limited validation, it is
therefore also used for the management of acute (postoper-
ative) pain in older people. Using a population-PK model-
ling approach, we performed a study to estimate the PK of
IV paracetamol and its variability in ﬁt older people using
a population PK-modelling approach. To illustrate target
attainment and variability of paracetamol PK in ﬁt older
people simulations were performed with current dosing
regimens (1000 mg every 6 h, every 8 h) and a Css-mean of
10 mg l–1 as target for effective analgesia [11].
Methods
Patients, study design and drug dosing
Data on paracetamol concentrations from a previous observa-
tional study in older, ﬁt subjects who underwent surgery were
analysed [12]. The design of that study is summarized here, as
it is relevant to this analysis. The study was conducted at the
Turku University Hospital, Turku, Finland, following ap-
proval by the Finnish Medicines Agency and registration
(EUDRACT 2006–001917-14) and included 30 older subjects
who underwent elective knee prosthesis operations. The ex-
clusion criteria were: use of strong inhibitors or inducers of
cytochrome P450 enzymes, having a signiﬁcant hepatic, re-
nal, neurological, haematological, endocrine, metabolic or
gastrointestinal disease, or a body mass index >35 kg m–2. Pa-
tients with diabetes mellitus were eligible unless they had sig-
niﬁcant renal involvement [12]. The clinical characteristics of
the subjects are shown in Table 1.
A single IV paracetamol infusion with a dose of 1000 mg
was administered over 15 min according to the postoperative
pain protocol. Blood was sampled at ﬁxed time-points,
namely before infusion (t = 0), during infusion (t = 7.5,
15 min), and after completion of the infusion (2.5, 5, 10,
15, 20, 30, 45, 60 min and 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18,
24 h after infusion). In total 22 samples per patient were
obtained.
Analytical assay
Paracetamol concentrations were determined by the
high-performance liquid chromatographic method at the
Department of Clinical Pharmacology, Helsinki and Helsinki
University Central Hospital, Helsinki, Finland [12, 13].
The assay was linear over 0.5–250 μg ml–1. The lower limit
of quantiﬁcation (LLOQ) was 0.25 mg l–1. Intra- and
interassay accuracies were < 5% and < 7%, respectively.
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Intra- and interassay imprecision did not exceed 15%. Further
details of the analytical assay are provided in the previous
published papers [12, 13].
Population PK analysis
Paracetamol was analysed using nonlinear mixed effect
modelling software NONMEM version 7.2 (ICON Develop-
ment Solutions, Ellicott City, MD) using the ﬁrst-order esti-
mation method with the interaction option (FOCE-I) and
subroutine ADVAN13, TOL6. Pirana (version 2.9.2), R (ver-
sion 3.3.0) and PsN® version (version 4.4.8) software were
used for graphical and numerical analysis of the output.
The model building process was performed stepwise as
follows: (i) the structural population model; (ii) the statistical
submodel; (iii) the covariate model; and (iv) internal valida-
tion. The different models were discriminated by the likeli-
hood ratio test using the objective function value (OFV; i.e.
–2*log likelihood), where a decrease in OFV of 7.8 points
(P < 0.005 based on a χ2 distribution) was considered statisti-
cally signiﬁcant, between nested models with one additional
degree of freedom. Furthermore, basic goodness-of-ﬁt-plots
were evaluated [14]. Additionally, the relative standard errors
(RSE), the condition number and the η-shrinkage of the ran-
dom effects were assessed during model evaluation. These
should be as low as possible but preferably not exceed 60%,
1000 and 25% respectively [14].
Structural and statistical model. For the structural model,
one, two and three compartment PK models for
paracetamol were tested. For the statistical model, inter-
individual variability on the model parameters was assumed
to be log-normally distributed and was tested for
signiﬁcance on all parameters. Variance were explored and
included by an omega block if applicable. For the residual
unexplained variability, a proportional, additive and a
combined error model were tested.
Covariate model. The tested covariates were body weight,
age, sex, creatinine concentration and creatinine clearance
(using Modiﬁcation of Diet in Renal Disease). To
visualize potential relationships, covariates were plotted
independently against the individual posthoc estimates of
the PK parameters. Continuous potential covariates were
tested using a linear or power equation (equation 1).
Pi ¼ θ1 COV
COVmedian
 θ2
þ θ3 (1)
In the equation, Pi represents the population parameter
estimates; θ1 and θ3 represent the population parameters esti-
mates (θ1 population factor of proportionality, θ3 population
intercept) for the covariate relationship and COV represents
the covariate value, which is normalized with the median co-
variate value (COVmedian) representing the median value of
the covariate for the full population. Θ2 is the population ex-
ponent, which was ﬁxed to 1 for a linear function or esti-
mated for a power function. For the categorical covariate
sex, the fractional change for one group compared to the
other group was calculated.
Potential covariates were entered one by one using the
bottom up inclusion method and considered statistically sig-
niﬁcant when the OFV decreased with at least 7.8 points
(P < 0.005). When more than one signiﬁcant covariate was
identiﬁed, the covariate causing the largest drop in OFV was
retained. For additional covariates to be retained in the
model, this OFV had to be educed with the use of the same
criteria. In addition, a reduction in interindividual variability
of the parameter was evaluated upon inclusion of the covari-
ate on the parameter.
Internal validation
For internal model validation, a bootstrap resampling
method to test the stability of themodel was conducted using
1000 replicates. Accuracy of the model was evaluated with
visual predictive checks (VPC). For this VPC a set of 1000
simulated datasets were created to compare the observed con-
centration with the distribution of simulated concentrations.
Simulations
IV administration-dosing regimens were simulated, with
1000 replicates per simulation, using the ﬁnal developed pop-
ulation PK model. The two dosing regimens frequently used
in clinical practice, namely 1000 mg administered during
15 min every 6 h (max 4000 mg per day) and 1000 mg every
8 h (max 3000 mg per day) were simulated for 48 h [5, 6].
For each simulated concentration–time proﬁle, the Css-mean
was calculated, based on the area under the plasma
concentration–time curve and divided by the dosing interval
during the ﬁnal dosing interval. In addition, for each concen-
tration time proﬁle the 10, 25, 50, 75 and 90 percentiles of the
Css were calculated.
Nomenclature of targets and ligands
Key ligand in this article are hyperlinked to corresponding
entries in http://www.guidetopharmacology.org, the com-
mon portal for data from the IUPHAR/BPS Guide to PHAR-
MACOLOGY [15], and are permanently archived in the
Concise Guide to PHARMACOLOGY 2017/18.
Table 1
Characteristics of 30 subjects
Variable
Male, % 12 (40)
Age, years 77.3 [61.8–88.5]
Weight, kg 79 [60–107]
ASA physical status
I -
II 17 (56.67)
III 11 (36.67)
IV 2 (6.67)
Creatinine (μmol l–1) 75 [50–147]
MDRD (ml min–1 1.73 m–2) 74.42 [29.56–116.8]
Values are presented as median [range] or n (%). ASA, American
Society of Anesthesiologists; MDRD, modiﬁcation of diet in renal
disease
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Results
Population PK analysis
The PK-model was based on 601 samples. Forty-seven sam-
ples (7.8%) were below the lower limit of quantiﬁcation
(LLOQ). The LLOQ occurred for samples taken after 10.25 h.
These samples were excluded from the analysis.
Structural and statistical model. A two-compartment model
best described the data (Figure 1). A three-compartment
model improved the OFV signiﬁcantly (dOFV = –53), but
the estimation of the second peripheral compartment
resulted in an unrealistic high volume of distribution (Vd
>1000 l) for this compartment and was therefore not
continued. A two-compartment model was estimated with
high precision (low RSEs) and therefore preferred over the
three-compartment model; the more so because the latter
showed limited improvement in the goodness-of-ﬁt plot.
Interindividual variability on all parameters signiﬁcantly
improved the model. Residual variability for paracetamol
was best described with a proportional error model. A sepa-
rate residual variability for paracetamol was estimated for
the early sample time-points (t = 7.5 and 15 min) during infu-
sion, due to a larger variability present.
Covariate model. For paracetamol, the systematic covariate
analysis identiﬁed sex as the most signiﬁcant covariate on
the central Vd (dOFV –21), implying a lower Vd in females
(1.8 times higher in males; Figure S1). As distribution of sex
over the age range was skewed in favour of women aged
>80 years; Figure S4), and as the relevance of this covariate
in the clinical setting is undeﬁned, this covariate was not
included in the model. In addition, colinearity was present
between body weight and sex (Pearson correlation of 0.69).
Body weight, in an exponential relationship, was identiﬁed
as the second-best explanatory variable for the Vd
(dOFV = –17), implying that the Vd increases in an
exponential relationship (Figure S2) with increasing body
weight. Thereafter, age decreased the CL of paracetamol
(dOFV = –10). However, this parameter could not be
accurately estimated (RSE 141%), and age was therefore not
included in the structural model (Figure S3). In addition,
the ω2 vs. the explored covariate plots did not alter after
adding age as a covariate on clearance (Figure S3).
The parameter estimates of the developed model are
shown in Table 2. Figure 2 demonstrates the goodness-of-ﬁt
plots. The data points show negligible bias around the line
of unity, indicating that the model accurately describes the
observations (Figure 2A,B,D). For the conditional weighted
residuals over time after dose (Figure 2C), a small bias was
retained in the model, which could not be further improved
by additional model development.
Internal validation
The bootstrap analysis was successful in 99.6% of the runs
and showed low variability in the stability of the model pa-
rameters (Table 2). The VPC plot, depicted in Figure 3, indi-
cates an overall good predictive performance (Figure 3A).
Figure 3B shows a small bias occurring in the time points
<0.25 h after sampling, inﬂuencing the predictive perfor-
mance. This small bias is due to the fact that sampling oc-
curred during infusion.
Simulations
Body weight was deﬁned as a major covariate contributing to
paracetamol Vd variability. However, due to remaining large
overlap in interindividual variability between a typical pa-
tient with the lowest interquartile range (66 kg), highest in-
terquartile range (85 kg) and median body weight (79 kg),
stratiﬁcation on body weight was not relevant (Figure 4).
Concentration–time proﬁles following the currently used
dosing regimens (1000 mg every 6 h or every 8 h) were pre-
dicted based on simulations using the developed PK model
(Table 3). After simulation of the currently used dosing regi-
mens, Css-mean of 9.2 and 7.2 mg l
–1 were obtained after ad-
ministration of 1000 mg every 6 h and every 8 h respectively.
Table 3 shows the targets achieved for 10, 25, 50, 75 and 90%
of the population. Variability in the population resulted in
90% of subjects being above a Css 5.4 and 4.1 mg l
–1 and 10%
above 15.5 and 11.7 mg l–1 at these dosing levels. When
looking at target attainment with the currently used dosing
regimens, 1000 mg every 8 h results in a Css far beneath the
analgesic target of 10 mg l–1.
Discussion
To our knowledge this is the ﬁrst study using a population-PK
approach that describes the PK of paracetamol and its vari-
ability in ﬁt older people. Based on the ﬁnal PK-model, simu-
lations were performed to illustrate target attainment and
variability to paracetamol PK following current dosing regi-
mens using Css-mean of 10 mg l
–1 as a target. The CL of
17 l h–1 and Vd of 85.2 l 79 kg–1 of paracetamol obtained by
this analysis are in line with those obtained from previous
(noncompartmental PK) analysis, 22.04–36.97 l h–1 79 kg–1
and 60.67–85.32 l 79 kg–1, respectively [10]. Adequate
Figure 1
Schematic overview of the population pharmacokinetic model of
paracetamol. V, distribution volume; CL, clearance of paracetamol;
Q, intercompartmental clearance of paracetamol between the cen-
tral and peripheral compartments
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achievement of the target concentration for a typical patient
wasobtainedafter simulationof1000mgevery6h (9.2mg l–1),
while the Css-mean obtained with 1000 mg every 8 h was far
below (7.2 mg l–1) the target for the average patient. Due to
the large variability in the PK, 10% of the subjects reached a
target concentration above 15.5 and 11.7 mg l–1 and 90%
were above 5.4 and 4.1 mg l–1 after administration of 1000
mg every 6 h and every 8 h, respectively. Other covariates
besides body weight that could explain this variability were
not identiﬁed. Identifying additional covariates, if any, is
necessary to optimize the individual dosing of paracetamol
in this highly heterogeneous population. Relevant issues
concerning model development, simulations and applicabil-
ity are discussed below.
Concerning the PK-model development, the current co-
variate analysis revealed that sex was the most signiﬁcant co-
variate, resulting in a 1.8-times higher Vd in males than
females. Five previous studies have investigated sex-related
differences in PK parameters between ﬁt older male and fe-
male adults [16–19]. In four, the Vd was lowest in females,
by 8.5–17.5% compared with males. Nevertheless, in only
one of these four studies the difference was statistically signif-
icant; P < 0.05), albeit not clinically relevant [20] The lower
Vd in women is probably caused by the larger proportion of
fat in women’s total body weight. The most plausible expla-
nation for the association between sex and Vd of paracetamol
is that other factors than sex play a role, such as body weight
(Pearson correlation of 0.69). Furthermore, the age group
>80 years consisted almost exclusively of women, which
might have contributed to the association (Figure S4). The
other signiﬁcant covariate that could (partly) explain vari-
ability between the older patients in the analysis was body
weight on Vd. The last signiﬁcant covariate was age on para-
cetamol CL. A large RSE (141%) was obtained when age was
added as covariate on CL of paracetamol; age was therefore
not included in the model. It is not surprising that age acts
as a potential covariate on the CL of paracetamol. In younger
subjects, clearance may be lower by the diminished phase II
conjugation [21]. A lack of covariates on CL in this study
could be due to the number of patients, which is relatively
small (n = 30) to describe the posthoc observed large differ-
ences between individuals since it was not anticipated that
variability, after IV administration in a ﬁt population, would
be so extensive. Furthermore, the lack of covariates could also
be caused by the exclusion criteria in the study design. Future
studies should therefore include more patients, primarily in
the older age range (> 75 years), to further explore the exact
inﬂuence of age and/or body weight on clearance. This would
increase the statistical power in the identiﬁcation of age-
related effects. Our ﬁnal PK-model showed great variability
that could not be explained by the covariates available for
this analysis. Therefore, we can only speculate about factors
affecting the remaining unexplained paracetamol CL vari-
ability within the ﬁt older people population.
Based on the ﬁnal PK-model, simulations were performed
with different dosing regimens currently used in clinical prac-
tice, using steady-state concentration (Css-mean) of 10 mg l
–1
as target for effective analgesia. Although this adequate
Table 2
Population pharmacokinetic parameters of the developed pharmacokinetic model for paracetamol in elderly and the values obtained after boot-
strap analysis
Final model: with covariates
(RSE%) [shrinkage %] Bootstrap mean [95%CI]
Population parameters
VAPAP, central = (θ1*((BW/79)** θ2) + θ3)
θ1 (l 79 kg
–1) 20 (11.2) 20.42 [7.73–50.99]
θ2 (l 79 kg
–1) 5.15 (8.9) 5.85 [2.65–10.98]
θ3 (l 79 kg
–1) 34.9 (9.9) 34.05 [10.62–43.10]
VAPAP, peripheral (l) 30.3 (35) 58.11 [14.38–88.31]
Q (l h–1) 3.54 (28.2) 4.03 [2.19–8.41]
CLAPAP (l h
–1) 17 (6.4) 16.9 [14.63–19.64]
Interindividual variability [ω2]
ω2 VAPAP, central 0.0976 (31.5) [0] 0.095 [0.04–0.155]
ω2 VAPAP, peripheral 1.38 (49.8) [1] 1.39 [0.21–2.55]
ω2 Q 2.01 (39.3) [29] 1.94 [0.66–3.35]
ω2 CLAPAP 0.113 (24) [12] 0.12 [–0.14–0.37]
Residual variability [σ2]
σ2 Proportional error (samples during infusion) 0.165 (37.3) [2] 0.167 [0.061–0.27]
σ2 Proportional error (samples after infusion) 0.0068 (16.7) [10] 0.0067 [0.005–0.009]
CI, conﬁdence interval; CLAPAP, elimination clearance of paracetamol; Q, intercompartmental clearance; RSE, relative standard error; VAPAP, central,
central volume of distribution of paracetamol; VAPAP, peripheral, peripheral volume of distribution of paracetamol
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analgesia was reached in the paediatric population, the target
concentration can be assumed to hold for older people as
well, albeit with limited validation. In recent years, clinical
experience has been gained with these regimens [5]. These
seem to be well tolerated, but underdosing and subsequently
suboptimal analgesia cannot be excluded. With 1000 mg ev-
ery 6 h, the average patient reaches a concentration of about
10 mg l–1 but, due to the large remaining unexplained
variability, a relevant portion of the ﬁt older people remains
off-target. For 1000 mg every 8 h, however, even the typical
patient does not reach the Css target concentration (Table 3).
Overall, we would argue that the administration of a higher
daily dose could result in better pain management. This view
was also supported by Piguet et al. [20] albeit in young adults
only. The authors reported that higher dosing of paracetamol
(1000 and 2000 mg in comparison with 500 mg) resulted in a
more pronounced dose-dependent central anti-nociceptive
effect in healthy adults [20]. Furthermore, obtaining the
optimal target concentration with the exact dosing of
paracetamol has the additional advantage that additional
opiate use can possibly be reduced.
When dosing paracetamol it is equally important, how-
ever, to reach the target concentration and to consider safety.
For older patients this safety aspect has resulted in the prac-
tice of dosing 1000 mg every 8 h [8]. Hepatotoxicity is com-
mon for paracetamol toxicity. Paracetamol is metabolized by
different metabolic pathways [21]. In young adults, these
are mainly the glucuronidation and sulfation pathways. A
minor pathway through cytochrome P450 2E1 results in
N-acetyl-p-benzoquinone imine (NAPQI), which is immedi-
ately neutralized by conjugation with glutathione [22]. After
formation of paracetamol–glutathione, both paracetamol–
cysteine and paracetamol–mercapturate are formed. How-
ever, at higher exposure or in situations where glutathione
is depleted, such as malnourished state, glutathione will be
depleted and NAPQI can bind covalently to cellular proteins
and form toxic protein adducts. This will cause mitochon-
drial dysfunction and early oxidant stress. Ultimately, this
will result in hepatocellular necrosis [22]. Several studies in
older people [23, 24] reported differences in the contributions
of the various metabolic routes as compared with younger
adults, probably caused by the changing proportions of glu-
curonide and sulfate. When dosing 1000 every 6 h instead
of every 8 h the exposure to NAPQI will be higher, although
it has been suggested that the fraction to oxidativemetabolite
seems unchanged in older people as compared with younger
Figure 2
Diagnostic plots for the ﬁnal pharmacokinetic model of paracetamol in older people: (A) observed concentrations vs. individual predicted
concentrations; (B) observed concentrations vs. population predicted concentrations; (C) conditional weighted residuals (CWRES) vs. time after
dose; (D) CWRES vs. population predicted concentrations
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Figure 3
Visual predictive checks of the ﬁnal pharmacokinetic model for paracetamol over the entire study period (A) and focus on the ﬁrst 5 h after para-
cetamol administration (B). The open circles represent observed concentrations. The upper, middle and lower lines indicate the 95th, 50th and 5th
percentile of observations, respectively. The shaded areas represent the 95% conﬁdence interval of the corresponding percentiles of predictions
Figure 4
Concentration–time proﬁles of 1000 mg every 6 h intravenous paracetamol for individuals with a bodyweight of 66 kg (red), 79 kg (green) and
85 kg (blue) and the 95% conﬁdence intervals, representing the lowest interquartile, median and highest interquartile body weight in this study
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adults [10]. Due to a larger remaining unexplained variability,
this can be a problem for a certain proportion of older people.
With the current PK model, this group of patients cannot be
identiﬁed. However, in this study, no information was avail-
able on all metabolites in order to investigate metabolite for-
mation, and neither was information on (liver) safety values
[12]. With 1000 mg every 6 h and every 8 h 10% was above
15.5 and 11.7 mg l–1, respectively. However, it has to be noted
that although the toxic reference of paracetamol has been re-
ported to be 75mg l–1 [25], hepatotoxicity can also occur with
normal dosages administered to young adults. In addition,
the toxic reference concentration of NAPQI is still unknown.
Future research should take into account both PK and safety
aspects. The postoperative clinical setting seems quite well-
suited to study both PK/PD and the safety of IV paracetamol
in ﬁt older people, because they receive paracetamol usually
no longer than 48–72 h and can be adequately monitored
(pain relief, safety). Future studies should focus on extending
this model to ﬁt older people using paracetamol orally, taking
into account that variability around the proposed target
concentration will be very likely to be even larger due to var-
iability in absorption rate constant and bioavailability. This
model can also be extended to investigate if other covariates
(e.g. type of surgery, those with several comorbidities and
Table 3
Summary statistics of achieved steady-state concentrations (Css) for intravenous paracetamol in ﬁt older people according to dosing regimens
used in clinical practice. For concentration–time proﬁles of these dosing regimens for ﬁt older people, refer to Figure 5
Css (mg l
–1)
25% of subjects
above
75% of subjects
above
90% of subjects
above
50% of subjects above
(mean concentration)
10% of subjects
above
1000 mg every 6 h 9.2 15.5 12.4 7.4 5.4
1000 mg every 8 h 7.2 11.7 9.4 5.4 4.1
Figure 5
Concentration–time proﬁles based on 1000 simulations using the ﬁnal PK model following the current dosing regimen every 6 h (A) and the cur-
rent dosing regimen every 8 h (B) in the ﬁrst 12 h dosing period (left) and the ﬁnal 12 h dosing period (right). The black line corresponds with the
median achieved concentration; the dotted lines represent the 25–75% prediction interval, the blue areas represents the 95% prediction interval
of the simulated values. The red dashed line indicates the target concentration of 10 mg l–1. The time above 10 mg l–1 is measured over the full
simulated 48 h period
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comedication) can explain interindividual variability in PK in
ﬁt older people. Themodel will be less usable for other special
populations within the older population, such as frail people,
due to reported changed PK parameters between ﬁt and frail
older people [10, 24, 26]. However, a suggestion could be to
perform a pooled-PK analysis of paracetamol in both ﬁt and
frail older people. Such a study has previously been done to
explore covariates in adults. [27]. Using this approach, the
impact of frailty as covariate can be further explored.
Conclusions
We conclude that paracetamol PK in ﬁt older people can be
best described with a two-compartment PK model. Body
weight was found to be themost important covariate contrib-
uting to the paracetamol Vd variability. Simulations of the
standardized dosing regimens (1000 mg) resulted in a Css of
9.2 and 7.2 mg l–1 for every 6 h and every 8 h respectively.
Thus, 1000 mg every 6 h achieved the target concentration
of 10 mg l–1 for the average patient, while every 8 h achieved
far below the target. However, on account of a large (unex-
plained) interindividual variability in paracetamol PK, a
relevant proportion of the ﬁt older people remained either
under- or overexposed, resulting in Css above 5.4 and
4.1 mg l–1, respectively, in 90% of the population and above
15.5 and 11.7, respectively, in 10% at these dosing levels.
With the current analysis, a ﬁrst step was made not only
to describe the PK of paracetamol, but also to illustrate
paracetamol exposure and variability with the currently used
dosing regimens in the setting of ﬁt older people. However,
the older population is a very heterogeneous group and vari-
ability increases when a population is studied with different
exclusion criteria. Besides exploring additional covariates in
ﬁt older persons, the next step is the expansion to a PK and
safety study in complex older populations, for example frail
older subjects or those with several comorbidities and
comedication.
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